SG11201403416TA - Compositions and methods for antibodies targeting factor p - Google Patents

Compositions and methods for antibodies targeting factor p

Info

Publication number
SG11201403416TA
SG11201403416TA SG11201403416TA SG11201403416TA SG11201403416TA SG 11201403416T A SG11201403416T A SG 11201403416TA SG 11201403416T A SG11201403416T A SG 11201403416TA SG 11201403416T A SG11201403416T A SG 11201403416TA SG 11201403416T A SG11201403416T A SG 11201403416TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
antibodies targeting
targeting factor
factor
Prior art date
Application number
SG11201403416TA
Other languages
English (en)
Inventor
Barbara Brannetti
Joy Ghosh
Ute Jaeger
Leslie Johnson
Yong-In Kim
Christian Carsten Silvester Kunz
Michael Roguska
Igor Splawski
Sha-Mei Liao
Michael Stefanidakis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201403416T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201403416TA publication Critical patent/SG11201403416TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201403416TA 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor p SG11201403416TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578458P 2011-12-21 2011-12-21
PCT/IB2012/057394 WO2013093762A1 (fr) 2011-12-21 2012-12-17 Compositions et procédés pour des anticorps ciblant le facteur p

Publications (1)

Publication Number Publication Date
SG11201403416TA true SG11201403416TA (en) 2014-07-30

Family

ID=47666430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201403416TA SG11201403416TA (en) 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor p
SG10201703249PA SG10201703249PA (en) 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor p

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201703249PA SG10201703249PA (en) 2011-12-21 2012-12-17 Compositions and methods for antibodies targeting factor p

Country Status (28)

Country Link
US (3) US9051365B2 (fr)
EP (2) EP3330288A1 (fr)
JP (2) JP6231493B2 (fr)
KR (1) KR102159843B1 (fr)
CN (2) CN104114576B (fr)
AP (1) AP2014007761A0 (fr)
AR (1) AR089393A1 (fr)
AU (4) AU2012356170B2 (fr)
BR (1) BR112014015111A2 (fr)
CA (1) CA2859493A1 (fr)
CL (2) CL2014001640A1 (fr)
CO (1) CO6990668A2 (fr)
CR (1) CR20140303A (fr)
CU (1) CU20140073A7 (fr)
EA (1) EA201491214A1 (fr)
ES (1) ES2728278T3 (fr)
HK (1) HK1254156A1 (fr)
IL (1) IL233279B (fr)
MA (1) MA35740B1 (fr)
MX (1) MX2014007665A (fr)
PE (1) PE20150159A1 (fr)
PH (1) PH12014501410A1 (fr)
SG (2) SG11201403416TA (fr)
TN (1) TN2014000258A1 (fr)
TW (1) TW201339174A (fr)
UY (1) UY34537A (fr)
WO (1) WO2013093762A1 (fr)
ZA (1) ZA201404432B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5815403B2 (ja) * 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
EP2726103B1 (fr) 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anticorps anti-properdine et leurs utilisations
US9051365B2 (en) 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P
CA3107182A1 (fr) * 2013-07-12 2015-01-15 Iveric Bio, Inc. Procedes pour traiter ou prevenir des etats ophtalmologiques
CA2943075C (fr) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Composes heterocycliques destines a etre utilises dans le traitement de troubles medies par pi3k-gamma
WO2015160975A2 (fr) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Polythérapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016191246A2 (fr) * 2015-05-22 2016-12-01 Memorial Sloan-Kettering Cancer Center Anticorps semblables aux récepteurs de lymphocytes t spécifiques pour un peptide prame
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
EP3573661A4 (fr) * 2017-01-30 2020-08-12 Alexion Pharmaceuticals, Inc. Anticorps anti-properdine monovalents et fragments d'anticorps
JP2020532285A (ja) 2017-07-11 2020-11-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５または血清アルブミンと結合するポリペプチドおよびその融合タンパク質
EP3697285A4 (fr) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. Biomarqueurs fonctionnels pour un traitement à base de statines dans la dégénérescence maculaire liée à l'âge (dmla)
GB2569144B (en) * 2017-12-06 2021-06-16 Proimmune Ltd Method for screening the activity of mutated expressed polypeptides
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
US20210187118A1 (en) 2018-05-18 2021-06-24 Daiichi Sankyo Co., Ltd. Anti-muc1 antibody-drug conjugate
WO2020058759A1 (fr) * 2018-09-17 2020-03-26 Kyoto University Administration d'un agent anti-c5 pour le traitement d'une lésion ou d'une insuffisance hépatique
EP3950953A4 (fr) * 2019-03-29 2023-04-19 Public University Corporation Yokohama City University Procédé de criblage et procédé d'évaluation de toxicité
WO2022125497A1 (fr) 2020-12-08 2022-06-16 Infinity Pharmaceuticals, Inc. Éganélisib destiné à être utilisé dans le traitement d'un cancer pd-l1 négatif

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (fr) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Proteines mutifonctionnelles a cible predeterminee
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (fr) 1989-10-25 1991-05-16 The University Of Melbourne MOLECULES RECEPTRICES Fc HYBRIDES
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (fr) 1990-08-29 1997-09-10 GenPharm International, Inc. production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2507749C (fr) 1991-12-13 2010-08-24 Xoma Corporation Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0714409A1 (fr) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Anticorps
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
MX9700764A (es) 1994-07-29 1997-05-31 Smithkline Beecham Plc Compuestos novedosos.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6087120A (en) 1996-02-02 2000-07-11 Haemoprobe B.V. Measurement of complement activation by biomaterials by means of complement convertase cleavage of peptide substrates
EP0904107B1 (fr) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
WO1998056906A1 (fr) 1997-06-11 1998-12-17 Thoegersen Hans Christian Module formant des trimeres
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
DE69835524T2 (de) 1997-08-26 2007-04-05 Amgen Fremont Inc. Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO1999054342A1 (fr) 1998-04-20 1999-10-28 Pablo Umana Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
EP1804064A1 (fr) 1999-02-19 2007-07-04 University Of Iowa Research Foundation Diagnostics et thérapeutiques pour la dégénérescence maculaire
JP2003506016A (ja) 1999-02-19 2003-02-18 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 動脈壁破裂障害のための診断剤および治療剤
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
DE60136272D1 (de) 2000-04-29 2008-12-04 Univ Iowa Res Found Diagnostika und therapeutika für makula degeneration erkrankungen
AU2001254847A1 (en) 2000-05-04 2001-11-12 Jussi Halleen Method for in vitro screening of drug candidates useful for the prevention of bone resorption
CA2441903C (fr) 2000-05-26 2012-07-31 National Research Council Of Canada Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
EP1186299A1 (fr) 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnostic, prévention et/ou traitement d' athérosclérose, infections et perturbations du système immunitaire
WO2002030985A2 (fr) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition de l'activation du complement c5 pour le traitement et la prevention du rejet differe d'une xenogreffe ou d'un rejet vasculaire aigu
CA2430013C (fr) 2000-11-30 2011-11-22 Medarex, Inc. Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains
ATE484522T1 (de) 2001-04-24 2010-10-15 Bayer Corp Menschliche antikörper gegen timp-1
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2002092780A2 (fr) 2001-05-17 2002-11-21 Diversa Corporation Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
EP1601377A4 (fr) 2003-02-21 2009-07-15 Genentech Inc Procedes de traitement et de prevention des lesions tissulaires associees aux blessures par reperfusion ischemique
US20070065433A1 (en) 2003-02-21 2007-03-22 Mollnes Tom E Methods and compositions for the treatment of meconium aspiration syndrome
US20070123466A1 (en) 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
ES2387275T3 (es) 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US7514539B2 (en) 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2654440C (fr) 2005-06-06 2013-09-03 Girish J. Kotwal Procedes de traitement ou de prophylaxie de l'atherosclerose et d'une lesion de reperfusion
AU2006301446B2 (en) 2005-10-12 2012-06-07 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
MX2008011323A (es) 2006-03-08 2008-11-18 Archemix Corp Aptameros que se unen al complemento y agentes anti-c5 utiles en el tratamiento de trastornos oculares.
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
CA2685208C (fr) * 2007-04-24 2014-04-08 Novelmed Therapeutics, Inc. Procedes et compositions permettant d'inhiber le complement et activation cellulaire a l'aide de dextran sulfate
CN101932337A (zh) 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
SI2262831T1 (sl) * 2008-03-03 2015-10-30 Novelmed Therapeutics, Inc. Protitelesa anti-properdina
WO2009121065A2 (fr) 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
WO2010016774A1 (fr) * 2008-08-04 2010-02-11 Fisher & Paykel Healthcare Limited Interface de fixation d'un masque respiratoire
JP5815403B2 (ja) * 2008-08-05 2015-11-17 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
EP2545075B1 (fr) * 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Anticorps anti-properdine humanisés et chimériques
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
EP2726103B1 (fr) * 2011-07-01 2018-09-05 The Trustees Of The University Of Pennsylvania Anticorps anti-properdine et leurs utilisations
US9051365B2 (en) * 2011-12-21 2015-06-09 Novartis Ag Antibodies that bind factor P

Also Published As

Publication number Publication date
NZ721643A (en) 2020-05-29
US9988440B2 (en) 2018-06-05
AU2016203134A1 (en) 2016-06-02
ES2728278T3 (es) 2019-10-23
CO6990668A2 (es) 2014-07-10
US10865237B2 (en) 2020-12-15
CR20140303A (es) 2015-01-16
UY34537A (es) 2013-07-31
AU2012356170A1 (en) 2014-07-10
JP2017192387A (ja) 2017-10-26
AU2020203047A1 (en) 2020-05-28
NZ626296A (en) 2016-12-23
TN2014000258A1 (en) 2015-09-30
CN106831985A (zh) 2017-06-13
JP6231493B2 (ja) 2017-11-15
KR20140117411A (ko) 2014-10-07
CN104114576A (zh) 2014-10-22
EP3330288A1 (fr) 2018-06-06
MA35740B1 (fr) 2014-12-01
BR112014015111A2 (pt) 2017-06-13
US20130295102A1 (en) 2013-11-07
KR102159843B1 (ko) 2020-09-24
PH12014501410A1 (en) 2014-09-22
JP6486407B2 (ja) 2019-03-20
AU2018219993A1 (en) 2018-09-06
CL2014001640A1 (es) 2014-12-05
IL233279A0 (en) 2014-08-31
SG10201703249PA (en) 2017-05-30
TW201339174A (zh) 2013-10-01
JP2015503909A (ja) 2015-02-05
CU20140073A7 (es) 2014-12-26
MX2014007665A (es) 2015-03-05
HK1254156A1 (zh) 2019-07-12
CL2016001256A1 (es) 2016-10-28
CN104114576B (zh) 2017-04-05
US20150158936A1 (en) 2015-06-11
US9051365B2 (en) 2015-06-09
EP2794656A1 (fr) 2014-10-29
EA201491214A1 (ru) 2015-02-27
EP2794656B1 (fr) 2019-02-27
AR089393A1 (es) 2014-08-20
CA2859493A1 (fr) 2013-06-27
IL233279B (en) 2020-10-29
WO2013093762A1 (fr) 2013-06-27
PE20150159A1 (es) 2015-02-08
AP2014007761A0 (en) 2014-07-31
US20180327486A1 (en) 2018-11-15
AU2012356170B2 (en) 2016-06-16
AU2016203134B2 (en) 2018-05-31
ZA201404432B (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL276234B (en) Antibody compositions
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
HK1254156A1 (zh) 用於抗體靶定p因子的組合物和方法
HK1243344A1 (zh) 抗體製劑和方法
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
ZA201602366B (en) Compositions and methods for antibodies targeting epo
SG10201602218VA (en) Novel fuel compositions and methods for making same
EP2756094A4 (fr) Anticorps anti-b7-h4 et leurs utilisations
ZA201308892B (en) Compositions and methods
EP2766357A4 (fr) Compositions méso-biliverdines et procédés associés
GB201116340D0 (en) Compositions and methods